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The first international consensus conference on continuous placement therapy (CRRT) [3] and use of this therapy
renal replacement therapy. is increasing worldwide. However, there are no standard
Background. Management of acute renal failure (ARF) in guidelines for the application of CRRT and practice pat-the critically ill is extremely variable and there are no published
terns vary widely between individual centers. Resultsstandards for the provision of renal replacement therapy in
from recent clinical trials on selection of dialysis mem-this population. We sought to review the available evidence,
make evidence-based practice recommendations, and delineate branes [4–7] and dialysis dose [8, 9] provide important
key questions for future study. evidence to guide therapy. Yet important questions re-
Methods. We undertook an evidence-based review of the
main unanswered. Finally, the method by which acuteliterature on continuous renal replacement therapy (CRRT)
organ support is provided can have a profound effect onusing MEDLINE searches. We determined a list of key ques-
tions and convened a 2-day consensus conference to develop patient mortality (e.g., transfusion thresholds [10] and
summary statements via a series of alternating breakout and ventilator management [11]) supporting the need to
plenary sessions. In these sessions, we identified supporting identify practice standards and key research questions.evidence and generated practice guidelines and/or directions
The purpose of this consensus conference was to reviewfor future research.
the available evidence regarding the optimal provisionResults. Of the 46 questions considered, we found consensus
for 20. We found inadequate evidence for 21 questions and of CRRT, make evidence-based practice recommenda-
for the remaining five we found data but no consensus. Full tions, and delineate key questions for future study.
versions of workgroup findings are available on the Internet
at www.ADQI.net.
Conclusions. Despite limited data, broad areas of consensus METHODSexist for use of CRRT and guideline development appears
feasible. Equally broad areas of disagreement also exist and Our consensus process relied on evidence where avail-
additional basic and applied research in acute renal failure is able and, in the absence of evidence, consensus expert
needed. opinion where possible [12]. This combined approach
has led previously to important practice guidelines with
wide adoption into clinical practice [13]. In contrast, ex-
Acute renal failure (ARF) is a common complication
pert opinion alone can ignore important evidence while
of critical illness [1, 2] and mortality remains over 50%.
evidence-based reviews can be conceptually flawed with-Despite several advances in treatment, consensus over
out expert opinion [14]. We conducted the consensusthe optimal way to deliver care does not exist. Today,
process in three stages: (1) pre-conference, (2) confer-approximately one fourth of all patients in the United
ence, and (3) post-conference.States with ARF are treated with continuous renal re-
Prior to the conference, we identified seven topics of
CRRT practice (Table 1). We selected these topics based
1 A complete list of authors can be found in the Appendix. on (1) the prevalence of the associated clinical problem;
(2) known or suspected variation in clinical practice; (3)Key words: continuous renal replacement therapy, acute renal failure,
continuous venovenous hemofiltration, hemodialysis. potential importance for clinical outcome; (4) potential
for development of evidence-based medicine guidelines;
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and (5) availability of scientific evidence. For each topic,and in revised form March 25, 2002
Accepted for publication June 11, 2002 we outlined a preliminary set of key questions. We then
invited an international panel, predominantly from the 2002 by the International Society of Nephrology
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Table 2. Evidence-based medicine levels and gradesTable 1. Topics covered and not covered in
the consensus conference
Levels of Evidence
Level I Randomized trials with low false positive () and lowTopics Included Topics Excluded
false negative () error (i.e., high power)
Definitions/nomenclature Indications for renal replacement Level II Randomized trials with high  error or low power
Patient selection for CRRT therapy Level III Non-randomized concurrent cohort studies
Solute control in CRRT Costs Level IV Non-randomized historic cohort studies
Membranes Drug dosing Level V Case series, case reports, expert opinion
Operational characteristics Blood purification in non-renal Grades of Recommendations
Access and anticoagulation failure conditions Grade A Supported by at least two level I studies
Fluid composition and Withholding and withdrawing Grade B Supported by only one level I study
management dialysis Grade C Supported level II studies
Grade D Supported by at least one level III study
Grade E Supported by only level IV or V studies
fields of nephrology and intensive care, based on their
expertise in CRRT. Panelists were assigned to three-
Assessment of consensus and recommendations forperson workgroups, with each workgroup addressing one
clinical practicekey topic. Each workgroup conducted literature searches
related to their topic questions via MEDLINE, bibliogra- Selection of patients for CRRT. Dialysis improves
phies of review articles, and participants’ files. Searches short-term survival in severe ARF (level III evidence,
were limited to English language articles. However, arti- but it is unlikely that higher level studies will ever be
cles written in other languages were used when identified conducted) [15, 16]. Although there is no consensus on
by workgroup members. During this stage, the scope of the exact indications for renal replacement therapy,
the conference was also defined and some topics were there is consensus that patients with severe ARF should
excluded (Table 1). be treated with acute renal replacement therapy (grade
We conducted a 2-day conference in August 2000, D). There is significant variation in the timing of inter-
vention using blood urea nitrogen (BUN), creatinine, orin New York, NY. We developed summary statements
urine output with up to twofold differences in the re-through a series of alternating breakout and plenary ses-
ported values of these variables at the time of initiationsions. In each breakout session, the workgroups refined
of renal replacement therapy [1, 6, 17, 18]. Thus, nothe key questions, identified the supporting evidence, and
recommendations on the timing of initiation of renalgenerated practice guidelines and/or directions for fu-
replacement therapy are possible beyond those definedture research as appropriate. We classified evidence by
by the conventional criteria that apply to chronic renallevels according to evidence-based medicine methodol-
failure patients (diuretic unresponsive pulmonary edema,ogy (Table 2) and provided qualitative commentary as
hyperkalemia, uremic complications, etc.) (grade D).necessary. However, we deferred critical appraisal of
However, since the consequences of these complicationsindividual studies to a later stage. We considered physio-
are likely to be more severe for critically ill patients withlogic, clinical, and economic outcomes separately. We
ARF, renal replacement therapy should usually begingenerated future research questions by identifying defi-
prior to their development (grade E). Renal replacementciencies in the literature and debating whether more
therapy should continue as long as the criteria definingevidence was necessary. Where possible, we also consid-
severe ARF are present (grade E). No further recom-ered pertinent study design issues. Workgroup members
mendations as to discontinuation of renal replacementpresented their findings during the plenary sessions, ro-
therapy can be made.tating responsibility for presenting to ensure full partici-
In keeping with the rationale for its development,pation. The workgroups then revised their drafts as
CRRT use has generally been reported in severely illneeded until a final version was agreed upon.
patients in the intensive care unit. In particular, CRRTA writing committee assembled the individual reports
is most often selected for patients with ARF who havefrom the workgroups and each report was edited to con-
hemodynamic instability and for patients in whom con-form to a uniform style and for length. The final reports
tinuous removal of volume or toxic substances is thoughtwere mailed to each participant for comment and revision.
desirable. The latter might include patients with ARF
who also have septic shock, acute respiratory distress syn-
RESULTS drome (ARDS), burns, or conditions with or, at risk for,
We considered a total of 46 questions and our results cerebral edema. In the absence of definitive evidence com-
paring CRRT to intermittent hemodialyis, no firm overallare summarized in Table 3. We report a summary of each
individual workgroup below. Full versions of workgroup recommendations for patient selection can be made.
However, CRRT use may be advantageous in the man-findings are available on the Internet at www.ADQI.net.
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Table 3. Summary of findings
State of Consensus Number of Questions Action/Recommendation
Consensus exists 20 Described in summary statement
Data available but no
consensus 5 EBM processa
1. Cellulose-based vs. synthetics membranes Statistical meta-analysis
2. CRRT vs. intermittent hemodialysis Multicentered clinical trial
3. Dialysis dose Guideline development (further study in IHD)
4. Catheter design and location Systematic review
5. Catheter insertion Guideline development
Insufficient evidence 21 Future research objectives outlined
a A formal evidence-based medicine (EBM) process was not undertaken as part of the consensus conference. However, in five key areas we determined that
sufficient evidence exists to warrant such a process. In the case of dialysis membranes, a statistical meta-analysis was recommended, while in the area of catheter
design and insertion site, a comprehensive systematic review will be necessary to integrate the data on safety, patency, and recirculation. With regard to dialysis dose
and catheter placement, sufficient data exist to establish formal guidelines, although some further study is still required; while, in the case of continuous (CRRT) vs.
intermittent therapy, an EBM process will be useful in designing a definitive trial.
agement of intensive care unit patients with ARF (grade ing evidence suggests the importance of using standard-
ized Kt/V or equivalent renal clearance to compare dis-E) and CRRT is recommended over intermittent hemo-
dialysis for patients with ARF who have, or are at risk parate therapies and different frequencies of treatment
[31]. For pure hemofiltration the ultrafiltration rate andfor, cerebral edema (grade C) [19–21]. There is insuffi-
cient evidence to recommend the use of CRRT for non- sieving coefficient for a marker can be used to measure
clearance. For other modalities, dialysate plus ultrafil-ARF indications outside clinical investigation (grade E).
Solute control (treatment dose). The exact identity and trate flow and concentration are required to measure
clearance (grade C). Clearance is typically factored forrelative importance of all uremic toxics are unknown.
Despite many decades of research, no single substance surface area, similar to kidney clearance or for urea
distribution volume similar to chronic dialysis (grade E).or group of substances have been directly related to
adverse effects. Urea is only a marker substance for Treatment dose affects outcome for stable patients
with end-stage renal disease (ESRD) [32], and recentthe clinical condition known as uremia [22]. Thus, it is
inappropriate to equate the clinical diagnosis of uremia level I [8] and level III [9] evidence supports a similar
relationship for patients with ARF. However, there iswith isolated blood levels of urea or creatinine (grade
C). Absolute levels of urea and creatinine are difficult no consensus on what the minimum dialysis dose should
be for ARF. Based on evidence from ESRD, a minimumto interpret as both high and low levels may indicate
poor outcome [23]. The rates of change of urea or creati- Kt/V of 1.2 should be delivered three times a week to
patients with ARF (grade A). However, higher doses ofnine levels may better reflect severity of renal failure
(i.e., rapid increases suggesting severe renal dysfunction) dialysis may be beneficial in critically ill patients with
ARF based on studies in CRRT (grade B). Specifically,[24–27]. Accordingly, there is broad consensus that se-
rum levels of urea or creatinine should be interpreted in an intensity of continuous venovenous hemofiltration
(CVVH) of 35 mL/kg/hour is associated with improvedthe context of their rates of change over time (grade C).
Similarly, during treatment, clearance of various marker survival compared to 20 mL/kg/hour in critically ill pa-
tients with ARF [8]. Finally, following our consensussubstances appears to be the best measurement of ther-
apy dose since mass transfer must be interpreted with conference, Schiffl, Lang, and Fischer [33] reported the
results of a randomized trial comparing alternate day tosteady-state blood levels to reflect clearance. Fractional
clearance may be even better. Furthermore, the use of daily intermittent hemodialysis showing a reduction in
mortality from 46% to 28%. Unfortunately, althoughblood solute concentrations to assess clearance must con-
sider solute generation rates [28–30]. Therefore, marker the prescribed dose of dialysis was 3.6 Kt/V per week in
the alternate day group, the delivered dose was far lessclearance should be used as the primary basis for CRRT
dosing (grade C), excepting that during pure filtration, (about 2.8), leaving the issue of a minimum weekly dose
of intermittent hemodialysis still unsettled. However,dose is proportional to ultrafiltration rate. Methods for
measuring and expressing CRRT clearance vary widely this latter study does support the concept that a dose-
response relationship exists for dialysis in ARF and sug-in clinical practice and include clearance (K) times dial-
ysis duration (t) divided by the volume of distribution gests that the traditional, ESRD-based, dose recommen-
dation may be too low.(V) to yield Kt/V (fractional clearance), or divided by
the body surface area (K/SA). Other measures include Membranes. Based on the clinical evidence at the
present time, recommendations about the use or avoid-the solute removal index (SRI), or simply ultrafiltration
rate for hemofiltration. There is no consensus as to which ance of specific membranes in CRRT cannot be made.
However, until proven otherwise, there is consensus thattechnique should be used in all clinical situations. Emerg-
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the use of synthetic in favor of cellulose-based mem- (grade C). Femoral vein thrombosis is a significant prob-
lem in neonates and young children and, thus, thesebranes is appropriate [4–7, 34, 35] (grade B). Although
not demonstrated conclusively to be of benefit, trans- vessels should be avoided if possible (grade D). Based
on available evidence, no recommendation can be mademembrane pressure monitoring and measurement of
urea sieving coefficient, urea equilibration ratio, and fil- regarding the risk of infection with various sites of cathe-
ter placement. Recirculation is likely to be significanttration fraction may all be employed to assess filter func-
tion (grade E). Filter choice requires special consider- for blood flow rates in excess of 200 mL/min, but will
vary depending on catheter design and location. Internalation for proper implementation of certain modalities,
such as high-volume hemofiltration, slow low-efficiency jugular locations are generally superior (grade C). Poly-
urethane catheters are preferable for CRRT accessdialysis (SLED), and extended daily dialysis (EDD). In
general we recommend the use of filters with higher (grade D). Silver coating is currently not effective and
antibiotic coating/impregnation has not been studied forwater permeability for high-volume hemofiltration and
dialyzers with large surface areas for SLED and EDD this indication. Vascular access sites should be managed in
accord with previously published recommendations [46].(grade E). Finally, hypersensitivity reactions may occur
with certain types of filters. However, there is insufficient Ultrasound guidance has been reported in level II and
III studies to reduce the failure and complication ratesevidence to produce specific recommendations regarding
this issue. of central venous catheter insertion [47–50]. Similarly,
infection rates and placement failure rates are less whenOperational characteristics. Based on the available
data, no recommendations regarding the use of predomi- catheters are placed by specialized/experienced vascular
access teams [51, 52]. Thus, the use of ultrasound guidancenantly convective therapies (i.e., CVVH) as compared
to diffusive therapies [i.e., continuous venovenous hemo- and specialized access teams is encouraged (grade C).
Anticoagulation. The choice of anticoagulant for CRRTdialysis CVVHD)] can be made. Efficiency of removal
of low-molecular-weight solutes is similar with convec- should be determined by patient characteristics, local
expertise, ease of monitoring (bed side vs. specializedtion and diffusion. Efficiency of middle- and high-molec-
ular-weight solute removal is greater with convective laboratory tests), and pharmacy issues (including prepar-
ing specialized replacement solutions) (grade E). Sys-therapies; however, there is no evidence that this en-
hanced solute removal influences clinical outcomes. The temic anticoagulation with heparin (standard unfraction-
ated, low-molecular-weight, or synthetic heparinoids),clinical relevance of differences in solute adsorption is
also unknown. Venovenous therapies are preferred to or direct thrombin inhibitors (hirudin and argatroban)
should probably be avoided in patients at high risk ofarteriovenous therapies due to the ability to provide
higher rates of solute clearance [36] and a reduced risk bleeding (grade E). There is no consensus currently on
which anticoagulant should be the first choice for allof complications [36, 37] (level III). Arteriovenous thera-
pies should be reserved for settings in which venovenous CRRT patients. In patients who are auto-anticoagulated,
or are at high risk of bleeding, consensus exists thattherapy cannot be provided due to the absence of ade-
quate equipment or personnel (grade D). There is no CRRT can be carried out successfully without any anti-
coagulation [53], although circuit life may be less thanconsensus regarding the appropriate qualifications for
personnel performing CRRT other than demonstration 24 hours (grade D). Regional citrate anticoagulation may
also be an option for such patients.of competency. Specifically, there are no data to support
the exclusive performance of these therapies by either When anticoagulation is used, safety monitoring is
recommended (grade E) although consensus does notintensivists or nephrologists, or by critical care or ne-
phrology nurses. We believe that these decisions need exist on the frequency or method. During heparin antico-
agulation, measurement of activated clotting times (ACT)to be resolved at individual health-care facilities, based
on available resources and the local competency and or systemic partial thromboplastin time (PTT) are readily
available. In addition, routine measurement of plateletscredentialing of physicians and nurses (grade E). The
criteria for this competency and credentialing have been should be made to monitor for heparin-induced throm-
bocytopenia. During citrate anticoagulation, frequent mea-addressed by medical and nursing professional societies.
Vascular access. There is currently no consensus on surements of post-filter and serum-ionized calcium should
be done to appropriately titrate the dose of citrate andvascular access, although the majority of recently pub-
lished reports suggest that most centers are now using calcium replacement solutions (grade E). Monitoring of
systemic acid-base balance is also advisable in patientssingle dual-lumen venous catheters. Venous access sites
include the subclavian, internal jugular, and femoral at high risk for citrate accumulation. Without additional
safety data, regional anticoagulation using heparin-prot-veins. The optimal site in any given patient is determined
by the risks of thrombosis and infection, ease of place- amine cannot be recommended given the risk of prot-
amine accumulation in patients with ARF. Low-molecu-ment, and adequacy of function [38–45]. Due to the risk
of thrombosis and late stenosis, if possible, subclavian lar-weight heparins and synthetic heparinoids require
regular monitoring of anti-factor Xa activity (grade E).veins should be avoided for CRRT access in adults
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There is insufficient evidence to recommend specific Recommendations for reporting of CRRT in the
medical literaturemonitoring strategies for these agents. Similarly, there
is no consensus on whether or how to monitor for filter CRRT is defined as any extracorporeal blood purifi-
performance during CRRT. cation therapy intended to substitute for impaired renal
Fluid composition and management. Dialysate or sub- function over an extended period of time and applied
stitution fluid used during CRRT should contain physio- for, or aimed at being applied for, 24 hours per day.
logic concentrations of electrolytes, except in patients Conversely, intermittent therapies are those usually pre-
with extreme imbalances (grade E). Supra-physiologic scribed for a period of 12 hours or less and include
concentrations of glucose found in some dialysis or sub- techniques classified as EDD and SLED. While the cur-
stitution fluids frequently result in excessive glucose in- rent definitions for the basic modes of CRRT (arterial
take and hyperglycemia [54, 55] and therefore should be or pump driven, filtration or dialysis, or both) should
avoided (grade E). Both lactate and bicarbonate are able continue to be used (Table 4) [61], definitions for new
to correct metabolic acidosis in most CRRT patients [56] techniques follow.
(level II). Worsening of acidosis has been noted when Continuous venovenous high-flux dialysis. Continu-
lactate was used in patients with lactic acidosis or liver ous venovenous high-flux dialysis (CVVHFD) is defined
failure [57] (level V). The use of citrate, mostly not ti- as a technique that uses a highly permeable dialyzer
trated to pH but for anticoagulation, has been associated with blood and dialysate flowing countercurrent. In this
with both metabolic alkalosis and metabolic acidosis [58] technique, blood pumps control ultrafiltrate production
(level IV). Thus, either lactate or bicarbonate can be and there is a balance of filtration and back-filtration
used as buffer in most CRRT patients (grade C), whereas with ultrafiltrate produced in the proximal portion of
bicarbonate is preferred in patients with lactic acidosis the fibers and reinfused by back-filtration in the distal
and /or liver failure (grade C) and in high-volume hemo- portion of the fibers so that replacement fluid is not
filtration (grade E). Fluids administered before the required [62, 63].
hemofilter (pre-dilution) appear to enhance the achiev- Continuous high-volume hemofiltration. Continuous
able ultrafiltration rate (this may be especially important high-volume hemofiltration is a variant of CVVH, which
in high-volume CVVH) and may be also useful in pa- requires higher surface area hemofilters and employs ul-
tients with frequent filter clotting (grade E) or, in combi- trafiltration volumes greater than 35 mL/hour/kg [63–65].
nation with post-dilution, when extracorporeal clearance Plasma therapies. The term “plasma therapies” should
is limited by the achievable blood flow (grade E). How- be used for any extracorporeal therapy that requires the
ever, no controlled studies provide adequate compari- separation of plasma from the formed elements of blood.
sons among these techniques. The term “hemoperfusion” should be reserved for treat-
While the use of sterile fluid for replacement is impera- ment in which blood or plasma is exposed to an adsorp-
tive, the bacteriological requirements for CRRT dialy- tive substance (charcoal, protein A, synthetic materials,
sate are less clear, except in high-flux dialysis where monoclonal antibodies, etc.) to remove toxins, solutes,
dialysate should probably be sterile because of back- or other materials.
filtration (grade E). Although reductions of body tem- To achieve status of a “new” CRRT technique, it
perature below 35C should probably be avoided (grade should be substantially different from existing modal-
E), available data do not allow us to make recommenda- ities. Otherwise these approaches should be classified
tions on whether CRRT fluids should be warmed. Inte- as a subgroup of an existing modality. Our suggested
grated fluid balancing systems have important, albeit “minimal acceptable parameters” for reporting studies
theoretical, advantages. While there is no evidence that involving CRRT are shown in Table 5 and are critical
fluid removal, per se, improves outcome in critically ill for evaluation of studies using CRRT and comparisons
patients with or without ARF, there is limited evidence between CRRT and intermittent therapy. It is recog-
that volume overload is associated with adverse out- nized that technical reports describing technique modi-
comes. There is level II evidence to suggest that main- fications without outcome data may only report opera-
taining negative fluid balance decreases length of stay tional characteristics.
in the intensive care unit in patients with acute lung in-
Recommendations for future research in CRRTjury [59]. Therefore, volume overload should be avoided
(grade D), especially in patients with acute lung injury Observational/epidemiological studies
(grade C). Since adaptive use of intravenous infusion • Long-term outcomes (survival, quality of life, renal
pumps for CRRT has been shown to risk significant er- function, and need for chronic renal replacement) of
rors in fluid balance, these systems should be discouraged ARF, including assessment of the prognostic factors
when devices specifically designed for CRRT are avail- for these outcomes
• Early natural history studies of ARF; ideal charac-able [60] (grade D).
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Table 4. CRRT nomenclature
Abbreviation Definition Description
CAVH Continuous arteriovenous hemofiltration Driving force is patient’s blood pressure
Circuit is arteriovenous
Ultrafiltrate produced is replaced with a replacement solution
Ultrafiltration in excess of replacement results in patient volume loss
Solute removal is through convection
CVVH Continuous venovenous hemofiltration Driving force is external pump
Circuit is venovenous
Other features similar to CAVH
SCUF Slow continuous ultrafiltration Form of CAVH or CVVH not associated with fluid replacement
Primary aim is to achieve fluid removal in fluid overloaded states
CAVHD Continuous arteriovenous hemodialysis Driving force is patient’s blood pressure
Circuit is arteriovenous
Dialysate solution is delivered across membrane countercurrent to blood
flow at a rate substantially slower than blood flow rate; typical dialysate
flow rates are 1 to 2 L/hour
Fluid replacement is not routinely administered
Solute removal is by diffusion
CVVHD Continuous venovenous hemodialysis Driving force is external pump
Circuit is venovenous
Other features similar to CAVHD
CAVHDF Continuous arteriovenous hemodiafiltration Driving force is patient’s blood pressure
Circuit is arteriovenous
Dialysate solution is delivered across membrane countercurrent to blood
flow at a rate substantially slower than blood flow rate; typical dialysate
flow rates are 1 to 2 L/hour
Ultrafiltration volumes are optimized to exceed desired weight loss and
enhance solute clearance from convection
Fluid losses are replaced in part or completely with replacement solution
Solute removal is both diffusive and convective
CVVHDF Continuous venovenous hemodiafiltration Driving force is external pump
Circuit is venovenous
Other features similar to CAVHDF
Adapted from Bellomo R, Mehta RL, Ronco C: Am J Kid Dis 28(Suppl 3):S2–S7, 1996.
Table 5. Minimal reporting criteria for CRRT studies points and study of the relation of such markers to
timing and courseDefine operational characteristics
of treatments Report patient characteristics • Optimal frequency of filter changes in specific popu-
Membrane/dialyzer/filter Measure of time actually spent lations in terms of filter clotting, activation of com-
on therapy plement and leukocytes
Delivery device Surgical/trauma/medical/other
Anticoagulation and monitoring Co-interventions
Access and blood flow Measure of severity of illness Interventional trials
(e.g., APACHE II, SOFA, • Randomized controlled trial (RCT) of the effectLiano, CCF Score) at start of
of dialysis intensity (including alternative initiationtherapya
Ultrafiltration rates and Indication/s for CRRT times and dose) on clinical outcomes
technique for fluid balance • RCT of CRRT versus intermittent hemodialyis inReplacement fluid composition Reporting of integrated
intensive care unit patients with ARFand administration hemodynamic status and
vasopressor treatment • RCT comparing convective and diffusive therapies
Dialysate fluid composition and Outcomes, especially survival,
• Further study to assess the benefits or lack of benefitadministration short and long term,
morbidity and return of renal of tunneling catheters, topical antimicrobials to the
function exit site, and use of antibiotic and or antiseptic packs
Complications of therapy Functional status and quality
in patients treated with EDD/SLED, where thereof life
is continual connection and disconnection of thea The most appropriate score remains to be determined
CRRT circuit and antibiotic-coated venous dialysis
catheters
• Compare different anticoagulation regimes on filterteristics include selecting a population in which the
performance and circuit longevity with analysis oftiming of the insult is easily identifiable (e.g., rup-
cost and safetytured abdominal aortic aneurysm or major trauma);
• Compare lactate and bicarbonate-based fluids inin addition, we recommend careful “phenotyping”
of patients using several markers at many time high-volume hemofiltration
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Practice variations medicine techniques are needed to summarize and com-
bine the results of existing, albeit small, studies. In other• A survey of physician and nurse opinions about
cases (treatment dose and catheter placement methods),current practice patterns
existing evidence should be translated into clinical prac-• Observational studies of the clinical decision-mak-
tice guidelines. Finally, in the case of deciding betweening process in relation to stopping or transition to
available modalities (CRRT, intermittent hemodialy-a different modality
sis, EDD), further clinical trials are necessary with care-• Observational studies of physiologic status at time
ful attention to issues of patient selection and study de-of cessation or transition
sign [66].
One clear conclusion of this Acute Dialysis QualityCRRT in sepsis
Initiative (ADQI) is that more basic and applied re-• No further observational case series on the use of
search in CRRT is necessary. Our results detail 21 recom-conventional CRRT in sepsis
mendations for future studies. However, first and fore-• Recommend further evaluation by suitably powered
most, a uniform “working” definition/classification ofrandomized controlled trials
ARF for future studies is urgently needed [67]. More
than 30 biochemical definitions of ARF exist in the litera-Mechanistic/physiologic studies
ture and none has achieved wide acceptance. Research• Identification of the mechanism(s) of toxicity
and patient care are equally compromised by this lack• Biochemical identification, isolation and character-
of consensus.ization of the uremic toxin(s)
Beyond existing evidence and future research, the• Distribution and kinetics of various marker solutes
practical matter of providing care for patients with ARFin patients with ARF undergoing different treat-
must be addressed. Strategies are needed for developingment modalities
consensus and recommendations in the absence of evi-• Establishment of methodology to compare clear-
dence. At present, practice patterns for CRRT are ex-ance in disparate therapies and/or identify the best
tremely variable. Evidence from patient-level epidemio-parameter by which to measure dialysis dose
logic studies [17, 26] show that there is large variation• Better definition of kinetics of inflammatory media-
in the practice of CRRT. Surveys of United States [3]tors (generation and removal), with special consid-
and Australia physicians [17], as well as several largeeration of the effect of adsorption and back-trans-
case series [68], support this conclusion [69].port of solute
Uncertainty exists as to when to begin renal replace-• Effects of filter characteristics (high permeability,
ment therapy and when to stop. In the absence of evi-high adsroptivity) on middle/large molecule re-
dence, issues of timing, dose, and technique remain notmoval
only variable, but also extremely controversial. CRRT
is sometimes used for non-ARF indications, even thoughMeta-analysis/systematic review
there are no established non-ARF indications. Perhaps• Better characterization of the potential for adverse
the most pressing clinical question regarding the use ofevents related to blood-membrane interactions in
CRRT is to determine what patient and/or environmen-specific patient populations and with specific filters;
tal characteristics make CRRT desirable. Specifically,conflicting evidence needs to be reconciled
does CRRT offer an important survival advantage over• The risks of vascular thrombosis and infection with
intermittent hemodialysis in the management of ARFvascular access for CRRT in adults and children
[70]? Although combing evidence from multiple smallalong with the effects of different catheter designs,
reports appears to demonstrate a small survival advan-insertion site, catheter tip location and anticoagula-
tage with CRRT versus hemodialysis [66], definitive evi-tion on catheter performance and recirculation
dence is lacking. Thus, a large prospective RCT of CRRTrates; existing evidence needs to be integrated
versus intermittent hemodialysis in intensive care unit
patients with ARF is urgently needed. This study should
DISCUSSION feature careful “phenotyping” of patients, stratified ran-
After nearly a quarter of a century of clinical use domization of key subgroups (e.g., severity of illness),
and despite growing acceptance, there remain significant standardization of dialytic treatment (including dose and
deficiencies in our knowledge regarding CRRT and this membrane), and co-interventions (including drug use,
has led to variation in practice. However, despite a pau- nutrition, and non-renal organ support). Of note, the
city of level I evidence, there are broad areas of consen- consistent difference in baseline severity of illness, where
sus in the practice of CRRT. There are also limited areas CRRT patients are sicker, raises concern that physicians
where adequate data exist but where controversy per- involved in the study of CRRT may be reluctant to ran-
sists. In some cases (membrane biocompatibility, cathe- domize sicker patients to intermittent hemodialysis.
Thus, analogous to evaluation of the pulmonary arteryter design and insertion site) standard evidence-based
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5. Neveu H: Prognostic factors in acute renal failure due to sepsis.catheter, significant dedication to developing investiga-
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